Tongue neurostimulation for snoring and mild obstructive sleep apnea
Customize your policy alerts
Sign up for select_health Policy CCP.1559 alerts
Get alerted when Policy CCP.1559 changes without checking for updates manually.
Monitor payer policy activity
This policy governs coverage determinations for removable daytime intraoral tongue neurostimulation devices (e.g., eXciteOSA) used to treat primary snoring or mild obstructive sleep apnea in adults. It affects providers seeking reimbursement from Select Health of South Carolina.
No material clinical or coverage changes in this revision.
Coverage Determination
Not Covered / Investigational
Coverage determination:
Policy statement applies to all claims for these devices.
Tongue neurostimulation therapies, including eXciteOSA, are excluded from coverage as investigational when used to treat primary snoring or mild obstructive sleep apnea.
Tongue neurostimulation, including eXciteOSA, is considered not medically necessary for the treatment of snoring or mild obstructive sleep apnea.
Coding and Clinical Thresholds
| E0490 | Power source and control electronics unit for oral device/appliance for neuromuscular electrical stimulation of the tongue muscle, controlled by hardware remote. |
| E0491 | Oral device/appliance for neuromuscular electrical stimulation of the tongue muscle, used in conjunction with the power source and control electronics unit, controlled by hardware remote, 90-day supply. |
| E0492 | Power source and control electronics unit for oral device/appliance for neuromuscular electrical stimulation of the tongue muscle, controlled by phone application. |
| E0493 | Oral device/appliance for neuromuscular electrical stimulation of the tongue muscle, used in conjunction with the power source and control electronics unit, controlled by phone application, 90-day supply. |
| A9279 | Monitoring feature/device, stand-alone or integrated, any type, includes all accessories, components and electronics, not otherwise classified. |
Provider Billing and Action Notes
Prior authorization / coding — investigational; PA will not authorize coverage
Tongue neurostimulation devices and their supplies billed with HCPCS codes E0490, E0491, E0492, E0493, or A9279 are considered investigational and not medically necessary; prior authorization will not result in coverage under this policy.
Alternatives and step considerations
Labeling and clinical background describe other management options that should be considered depending on severity, anatomy, symptoms, and tolerance; the policy does not require a step-therapy sequence but lists common alternatives.
- Lifestyle measures
- Mandibular advancement devices (oral appliances)
- Positive airway pressure (PAP) therapy
- Surgical procedures
Labeling documentation notes
Device labeling recommends prescription use, awake-only use, dental assessment before use, repeat sleep testing when indicated, and regular follow-up with dental and sleep health professionals; these labeling elements should be documented if provided, although the device is excluded from coverage.
- Prescription use and awake-only use per labeling
- Dental assessment prior to device use
- Repeat sleep testing (e.g., to assess AHI)
- Regular follow-up with dental and sleep health professionals
Denial trigger — investigational / not medically necessary for snoring or mild OSA
Claims for tongue neurostimulation devices (including eXciteOSA) submitted for treatment of snoring or mild obstructive sleep apnea will be denied as investigational/not medically necessary.
- Policy statement applies to all claims for these devices for snoring or mild OSA
Background
Removable daytime intraoral neuromuscular electrical stimulation therapy (commonly referenced by the trade name eXciteOSA) is a mouthpiece-based device system with electrodes and a control unit that delivers targeted electrical stimulation to intrinsic and extrinsic tongue muscles. It is intended to be used for short daytime sessions to train tongue musculature and increase tongue tone, with the goal of improving upper airway patency and reducing snoring and obstructive events.
Device labeling describes typical use as daily, brief sessions (for example, 20 minutes per day over a specified period) and recommends prescription use, dental assessment before initiation, repeat sleep testing, and follow-up with dental and sleep health professionals; however, these devices remain investigational and are not covered under this policy.
Definitions
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.